Skip to content
Biodatica
Start free

Investigator

Randall J. Kimple

UNIVERSITY OF WISCONSIN-MADISON · funded by NIDCR, NCI

Companies
1

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$1.4M

Summed across those awards.

First award
Apr 25, 1997

Latest Apr 1, 2023.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. UH3

    Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomia

    $340k

    Apr 1, 2023NIDCRUNIVERSITY OF WISCONSIN-MADISONNIH RePORTER · 11061779 (opens the source filing in a new tab)

  2. R37

    Improving the translational value of head and neck cancer patient-in-mouse models

    $500k

    Jul 1, 2021NCIUNIVERSITY OF WISCONSIN-MADISONNIH RePORTER · 11114051 (opens the source filing in a new tab)

  3. R37

    Improving the translational value of head and neck cancer patient-in-mouse models

    $85k

    Jul 1, 2021NCIUNIVERSITY OF WISCONSIN-MADISONNIH RePORTER · 11211997 (opens the source filing in a new tab)

  4. UH3

    Intra-salivary gland autotransplantation of marrow mesenchymal stromal cells for treatment of radiation induced xerostomia

    $340k

    Jul 1, 2021NIDCRUNIVERSITY OF WISCONSIN-MADISONNIH RePORTER · 11368829 (opens the source filing in a new tab)

  5. P30

    Imaging and Radiation Sciences

    $103k

    Apr 25, 1997NCIUNIVERSITY OF WISCONSIN-MADISONNIH RePORTER · 11178530 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources